AWARE INC /MA/

AWARE INC /MA/ Q3 FY2018 earnings

AWRE

Quarter ended Sep 2018.

← Q2 FY2018Q4 FY2018 →
Revenue
$5.4M
+1474.6% YoY
Operating margin
21.1%
-464.3 pp YoY
Net income
$1.3M
+3.9% YoY

Summary

The company's fiscal 2018 third quarter showed a split performance. Revenue was $5.4 million, down 5.4% from the prior-year quarter. Operating income fell 23.5% to $1.1 million, and operating margin was 21.1%, down 5.0 percentage points. Net income moved in the opposite direction. It rose 11.5% to $1.3 million, and diluted EPS was $0.06, up 20.0%. Interest income increased and income tax expense was lower than in the prior-year quarter, which helped the bottom line even as operating profit declined. The company adopted ASC 606 on January 1, 2018, using the full retrospective method, so prior-year figures reflect restated results.

The nine-month picture is much weaker. Revenue for the first nine months was $12.1 million, down 2.7%. Operating income was $38,000, down 97.9%. Net income was $0.6 million, down 61.9%, and diluted EPS was $0.03, down 57.1%. Operating margin was 0.3%, down 14.0 percentage points. The year-to-date operating margin of 0.3% shows how thin operating profitability has been through nine months.

Revenue mix shifted during the quarter. Software license revenue declined, driven by lower imaging software license sales, which were only partly offset by higher biometrics software license sales. The imaging decline stemmed from a medical imaging software license agreement signed in the third quarter of 2017 that had no counterpart in the current quarter. The biometrics increase came from a new software license agreement with a large commercial customer and from a systems integrator agreement signed in the second quarter of 2018. Maintenance revenue and services revenue both grew, and each became a larger share of total revenue. Royalties fell to zero. Cost of software licenses decreased, while cost of services increased. Research and development expense decreased, selling and marketing expense increased, and general and administrative expense decreased. Patent related income was minimal in the quarter and much lower than a year earlier. Services backlog was $1.3 million at September 30, 2018. Management expects development work on the systems integrator project to continue for approximately the next three to four quarters, and it expects further cost of services from that project over the same period.

Cash generation was weak. Operating cash flow was $19,000 in the quarter, down 94.5%. For the first nine months, operating cash flow was -$2.16 million, down 454.0%. Capital expenditures were $8,000 in the quarter, flat versus the prior-year quarter, and $142,000 for the first nine months, up 132.8%. Deferred revenue was $3.12 million at September 30, 2018, and remaining performance obligations were $0.10 million. Management said it believes cash and cash equivalents will be sufficient to fund operations for at least the next twelve months. The company also has a stock repurchase program and an employee stock purchase program, which it used during the nine-month period.

Risks remain tied to the business mix. The company depends on winning biometrics systems projects and on expanding into commercial biometrics markets, which it describes as emerging. It also faces unpredictable patent monetization income, and it does not expect future DSL royalties. On taxes, the company has deferred tax assets with no valuation allowance, but it will continue to assess whether a valuation allowance is needed. A change in evidence about realizability could lead to an adjustment. The large systems integrator project is a near-term revenue and cost driver. Revenue from commercial markets is difficult to predict, and the company says it is unable to predict how much more income it might receive from its patent arrangement.

The quarter's headline numbers show a business that is still profitable but under pressure. Net income and EPS improved, yet revenue, operating income, and operating margin all declined. The nine-month results are weaker still, with operating income of $38,000 and operating cash flow of -$2.16 million. Deferred revenue was $3.12 million, and management expects the systems integrator project to support services revenue for the next three to four quarters. The main question for the next few quarters is whether biometrics license growth can offset the sharp swing in imaging revenue and the loss of patent and royalty income.

Forecast

Management guidance

No forward guidance in this quarter's filings.

Reported figures

GAAP, from SEC filings
MetricQ3 FY2018Q2 FY2018QoQQ3 FY2017YoY
Revenue$5.4M$3.8M+43.6%$343.0K+1474.6%
Research & development$1.8M$1.9M-3.8%$2.2M-15.6%
Sales & marketing$1.3M$1.0M+28.0%$1.1M+23.1%
General & administrative$807.0K$871.0K-7.3%$849.0K-4.9%
Total operating expenses$4.3M$4.1M+2.9%$4.3M+0.0%
Operating income (loss)$1.1M-$381.0K+399.7%$1.7M-31.4%
Operating margin21.1%-10.1%+31.3 pp485.4%-464.3 pp
Net income (loss)$1.3M-$188.0K+779.3%$1.2M+3.9%
Net margin23.6%-5.0%+28.6 pp358.3%-334.7 pp
Diluted EPS$0.06-$0.01+$0.07$0.06±$0.00

Risks

HIGHRevenue Concentration

MD&A states a systems integrator software license agreement signed in Q2 2018 contributed $0.6 million of software license revenue in Q3 2018 and $1.2 million in the first nine months of 2018, and a large commercial customer also drove biometrics license sales. This dependence on a small number of large contracts makes revenue sensitive to project timing and customer renewal.

HIGHOperating Performance

Revenue for FY2018 Q3 was $5.40 million, down 5.4% from FY2017 Q3, and operating income was $1.14 million, down 23.5%. For the nine months ended September 30, 2018, operating income was $38,000, down 97.9% from $1.78 million, and operating margin was 0.3%, down 14.0 percentage points, driven by lower imaging revenue and lower patent related income.

MEDIUMPatent Income

MD&A reports patent related income was $1,000 in both the three and nine months ended September 30, 2018, compared with $19,000 and $1.4 million in the prior year periods. Royalties also decreased 100% to zero, and management believes it is unlikely to receive DSL royalties in future periods, reducing a non-core income source.

MEDIUMCash Flow

Operating cash flow was $0.02 million in FY2018 Q3, down 94.5% from $0.34 million in FY2017 Q3, and was down to negative $2.16 million for the first nine months of 2018 from positive $0.61 million in the prior year period. Cash and cash equivalents decreased $2.6 million from December 31, 2017 to $49.0 million at September 30, 2018.

MEDIUMCommercial Expansion

Management's strategy includes expanding into new commercial biometrics markets, but MD&A states it is unable to predict future revenue from these markets because they are emerging. This creates uncertainty around the timing and scale of a key growth initiative.

MEDIUMProject Execution

MD&A says development effort on a large systems integrator project is expected to continue for approximately the next three to four quarters, and cost of services increased 79% in Q3 2018 and 48% in the first nine months of 2018. Services backlog was $1.3 million as of September 30, 2018, so cost overruns or project delays could pressure margins.

LOWTax Valuation

As of September 30, 2018, the company had $5.2 million of deferred tax assets with no valuation allowance. Management states that should evidence regarding realizability change in the future, the valuation allowance will be adjusted, which could increase tax expense and reduce net income.

Summary, forecast, risks and KPIs are extracted from AWARE INC /MA/'s SEC filings for Q3 FY2018 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Nov 12, 2026.